Brief: Simcere Pharmaceutical Enters Exclusive Licensing Agreement With Boehringer Ingelheim
27/01/2026 08:38
Jan 27 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK: ENTERS EXCLUSIVE LICENSING AGREEMENT WITH BOEHRINGER INGELHEIM BOEHRINGER INGELHEIM GRANTED EXCLUSIVE RIGHTS TO SIM0709 OUTSIDE GREATER CHINA ELIGIBLE FOR EUR42 MILLION UPFRONT AND UP TO EUR1,016 MILLION IN MILESTONES Further company coverage: 2096.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660